Rxwire
In the news · 48h FDA 38 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Daiichi Sankyo 2
Deals & business · first seen yesterday, updated yesterday

BoomRay and Novartis sign $900m deal for radioligand therapy

4 outlets Novartis

BoomRay Pharmaceuticals and Novartis have signed an exclusive worldwide licence deal for an undisclosed preclinical RLT asset in a deal worth up to $900m.

Summary from Pharmaceutical Technology.

Coverage 4 articles · 4 outlets

  1. Pharmaceutical Technology
    BoomRay and Novartis sign $900m deal for radioligand therapy
  2. Pharmaceutical Business Review
    BoomRay and Novartis Pharma sign $900m deal for radioligand therapy
  3. BioWorld Articles
    Novartis locks in preclinical RLT under $900M Boomray deal
  4. BioSpace - All News
    Novartis bets up to $900M for radioligand therapy from China’s BoomRay